REFERENCES
1. WHO Health Statistics. Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer [Last accessed on 3 Jan 2023].
2. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53.
3. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 2018;68:723-50.
4. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
5. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
6. Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51.
7. Jácome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. JAMA Netw Open 2021;4:e2136128.
8. Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
9. Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-effectiveness analysis of selective internal radiotherapy with Yttrium-90 versus sorafenib in locally advanced hepatocellular carcinoma. JCO Oncol Pract 2021;17:e266-77.
10. Williams SJ, Rilling WS, White SB. Quality of life and cost considerations: Y-90 radioembolization. Semin Intervent Radiol 2021;38:482-7.
11. Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology 2022;303:699-710.
12. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-45.
13. Abouchaleh N, Gabr A, Ali R, et al. 90Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med 2018;59:1042-8.
14. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29.
15. Chen CP. Role of external beam radiotherapy in hepatocellular carcinoma. Clin Liver Dis 2020;24:701-17.
16. Saini A, Wallace A, Alzubaidi S, et al. History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med 2019;8:55.
17. Kielar A, Fowler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-30.
18. Woerner AJ, Johnson GE. Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma. HR 2022; doi: 10.20517/2394-5079.2021.122.
19. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005;25 Suppl 1:S41-55.
20. Salem R, Gordon AC, Mouli S, et al. Y-90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-1163.e2.
21. Boston Scientific Clinical Trials. Bridging and downstaging to surgery hepatology: liver transplantation following Y-90 for HCC. Available from: https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology/cancer-therapies-ablation/therasphere/proven-results/bridging-and-downstaging-to-surgery.html [Last accessed on 3 Jan 2023].
23. Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: a mini-review. World J Gastrointest Oncol 2019;11:367-76.
24. Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for hepatocellular carcinoma: 8-year experience from a regional transplant center. J Gastrointest Cancer 2018;49:463-9.
25. Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review. Radiother Oncol 2018;129:112-22.
26. Montazeri SA, De la Garza-Ramos C, Lewis AR, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging 2022;49:3892-7.
27. Okada M, Numata K, Nihonmatsu H, et al. Pathological appearance of focal liver reactions after radiotherapy for hepatocellular carcinoma. Diagnostics (Basel) 2022;12:1072.
28. Aslam A, Do RKG, Kambadakone A, et al. Hepatocellular carcinoma liver imaging reporting and data systems treatment response assessment: lessons learned and future directions. World J Hepatol 2020;12:738-53.
29. Voizard N, Cerny M, Assad A, et al. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging 2019;10:121.
30. Ram R, Kampalath R, Shenoy-Bhangle AS, Arora S, Kielar AZ, Mendiratta-Lala M. LI-RADS treatment response lexicon: review, refresh and resolve with emerging data. Abdom Radiol (NY) 2021;46:3549-57.
31. Sato Y, Watanabe H, Sone M, et al. Japan Interventional Radiology in Oncology Study Group-JIVROSG. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 2013;118:16-22.
32. Chaudhry M, McGinty KA, Mervak B, et al. The LI-RADS version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma. Radiology 2020;294:320-6.
33. Shropshire EL, Chaudhry M, Miller CM, et al. LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 2019;292:226-34.
34. Kim SW, Joo I, Kim HC, et al. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-70.
35. Mendiratta-Lala M, Aslam A, Maturen KE, et al. LI-RADS treatment response algorithm: performance and diagnostic accuracy with radiologic-pathologic explant correlation in patients with sbrt-treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2022;112:704-14.
36. Yoon J, Lee S, Shin J, Kim SS, Kim GM, Won JY. LI-RADS version 2018 treatment response algorithm: diagnostic performance after transarterial radioembolization for hepatocellular carcinoma. Korean J Radiol 2021;22:1279-88.
37. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
38. Fournier L, Ammari S, Thiam R, Cuénod CA. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagn Interv Imaging 2014;95:689-703.
39. Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? Radiology 2012;262:708-18.
40. Xu M, Fraum T, Garcia-Aroz S, et al. Predictive value of mRECIST in HCC response to the neoadjuvant locoregional therapies and prognosis affected by the peak afp level before liver transplantation. Available from: https://atcmeetingabstracts.com/abstract/predictive-value-of-mrecist-in-hcc-response-to-the-neoadjuvant-locoregional-therapies-and-prognosis-affected-by-the-peak-afp-level-before-liver-transplantation/ [Last accessed on 3 Jan 2023].
41. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342-52.
42. Toskich B, Vidal LL, Olson MT, et al. Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation Study. J Vasc Interv Radiol 2021;32:518-526.e1.
43. Park S, Joo I, Lee DH, et al. Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: adding ancillary features to mri compared with enhancement patterns at CT and MRI. Radiology 2020;296:554-61.
44. Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y-90 radioembolization for primary liver malignancies. Abdom Imaging 2009;34:566-81.
45. Mendiratta-Lala M, Masch W, Shankar PR, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. Int J Radiat Oncol Biol Phys 2019;103:169-79.
46. Mendiratta-Lala M, Masch WR, Shampain K, et al. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiol Imaging Cancer 2020;2:e190024.
47. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49:1185-93.
48. Yu MH, Kim YJ, Park HS, Jung SI, Jeon HJ. Imaging patterns of intratumoral calcification in the abdominopelvic cavity. Korean J Radiol 2017;18:323-35.
49. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007;25:1099-106.
50. Park HJ, Kim SH, Jang KM, et al. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease. AJR Am J Roentgenol 2014;202:92-101.
51. Altenbernd J, Wetter A, Forsting M, Umutlu L. Treatment response after radioembolisation in patients with hepatocellular carcinoma-An evaluation with dual energy computed-tomography. Eur J Radiol Open 2016;3:230-5.
52. Funaoka A, Numata K, Takeda A, et al. Use of contrast-enhanced ultrasound with sonazoid for evaluating the radiotherapy efficacy for hepatocellular carcinoma. Diagnostics (Basel) 2021;11:486.
53. Delaney LJ, Tantawi M, Wessner CE, et al. Predicting long-term hepatocellular carcinoma response to transarterial radioembolization using contrast-enhanced ultrasound: initial experiences. Ultrasound Med Biol 2021;47:2523-31.
54. Eisenbrey JR, Forsberg F, Wessner CE, et al. US-triggered microbubble destruction for augmenting hepatocellular carcinoma response to transarterial radioembolization: a randomized pilot clinical trial. Radiology 2021;298:450-7.
55. Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008;14:5738-43.
56. Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 2014;83:1665-71.
57. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. SHARP investigators study group. plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
58. Nam JY, Lee JH, Bae J, et al. Novel model to predict HCC recurrence after liver transplantation obtained using deep learning: a multicenter study. Cancers (Basel) 2020;12:2791.
59. Abajian A, Murali N, Savic LJ, et al. Predicting treatment response to intra-arterial therapies for hepatocellular carcinoma with the use of supervised machine learning-an artificial intelligence concept. J Vasc Interv Radiol 2018;29:850-857.e1.
